Header Logo

Connection

Anil Chandraker to Heart Transplantation

This is a "connection" page, showing publications Anil Chandraker has written about Heart Transplantation.
Connection Strength

3.894
  1. Riella LV, Yang J, Chock S, Safa K, Magee CN, Vanguri V, Elyaman W, Lahoud Y, Yagita H, Abdi R, Najafian N, Medina-Pestana JO, Chandraker A. Jagged2-signaling promotes IL-6-dependent transplant rejection. Eur J Immunol. 2013 Jun; 43(6):1449-58.
    View in: PubMed
    Score: 0.372
  2. Riella LV, Liu T, Yang J, Chock S, Shimizu T, Mfarrej B, Batal I, Xiao X, Sayegh MH, Chandraker A. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant. 2012 Apr; 12(4):846-55.
    View in: PubMed
    Score: 0.341
  3. Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, Sayegh MH, Chandraker A. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant. 2009 Dec; 9(12):2837-44.
    View in: PubMed
    Score: 0.291
  4. Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, Dada S, Guleria I, Tian C, Ansari MJ, Shin T, Yagita H, Azuma M, Sayegh MH, Chandraker A. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008 Feb 05; 117(5):660-9.
    View in: PubMed
    Score: 0.258
  5. Pendse SS, Vadivel N, Ramos E, Mudge GH, Von Visger T, Fang JC, Chandraker A. BK viral reactivation in cardiac transplant patients: evidence for a double-hit hypothesis. J Heart Lung Transplant. 2006 Jul; 25(7):814-9.
    View in: PubMed
    Score: 0.232
  6. Chandraker A, Huurman V, Hallett K, Yuan X, Tector AJ, Park CH, Lu E, Zavazava N, Oaks M. CTLA-4 is important in maintaining long-term survival of cardiac allografts. Transplantation. 2005 Apr 27; 79(8):897-903.
    View in: PubMed
    Score: 0.213
  7. Yuan X, Dong VM, Coito AJ, Waaga AM, Salama AD, Benjamin CD, Sayegh MH, Chandraker A. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation. 2002 Jun 15; 73(11):1736-42.
    View in: PubMed
    Score: 0.175
  8. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation. 2002 Apr 27; 73(8):1310-7.
    View in: PubMed
    Score: 0.173
  9. Cai S, Choi JY, Borges TJ, Zhang H, Miao J, Ichimura T, Li X, Xu S, Chu P, Eskandari SK, Allos H, Alhaddad JB, Muhsin SA, Yatim K, Riella LV, Sage PT, Chandraker AK, Azzi JR. Donor myeloid derived suppressor cells (MDSCs) prolong allogeneic cardiac graft survival through programming of recipient myeloid cells in vivo. Sci Rep. 2020 08 28; 10(1):14249.
    View in: PubMed
    Score: 0.154
  10. Starling RC, Armstrong B, Bridges ND, Eisen H, Givertz MM, Kfoury AG, Kobashigawa J, Ikle D, Morrison Y, Pinney S, Stehlik J, Tripathi S, Sayegh MH, Chandraker A. Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. J Am Coll Cardiol. 2019 07 09; 74(1):36-51.
    View in: PubMed
    Score: 0.143
  11. Stehlik J, Armstrong B, Baran DA, Bridges ND, Chandraker A, Gordon R, De Marco T, Givertz MM, Heroux A, Ikl? D, Hunt J, Kfoury AG, Madsen JC, Morrison Y, Feller E, Pinney S, Tripathi S, Heeger PS, Starling RC. Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. Am J Transplant. 2019 05; 19(5):1518-1528.
    View in: PubMed
    Score: 0.138
  12. D'Addio F, Vergani A, Potena L, Maestroni A, Usuelli V, Ben Nasr M, Bassi R, Tezza S, Dellepiane S, El Essawy B, Iascone M, Iacovoni A, Borgese L, Liu K, Visner G, Dhe-Paganon S, Corradi D, Abdi R, Starling RC, Folli F, Zuccotti GV, Sayegh MH, Heeger PS, Chandraker A, Grigioni F, Fiorina P. P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. J Clin Invest. 2018 08 01; 128(8):3490-3503.
    View in: PubMed
    Score: 0.133
  13. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation. 1997 Apr 27; 63(8):1053-8.
    View in: PubMed
    Score: 0.123
  14. Ueno T, Jung K, Yeung MY, McGrath MM, Shimizu T, Kim P, Sayegh MH, Chandraker A, Yun SH. Imaging cell biology in transplantation. Transpl Int. 2016 Dec; 29(12):1349-1351.
    View in: PubMed
    Score: 0.118
  15. Javaheri A, Molina M, Zamani P, Rodrigues A, Novak E, Chambers S, Stutman P, Maslanek W, Williams M, Lilly SM, Heeger P, Sayegh MH, Chandraker A, Briscoe DM, Daly KP, Starling R, Ikle D, Christie J, Rame JE, Goldberg LR, Billheimer J, Rader DJ. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2016 11; 35(11):1295-1302.
    View in: PubMed
    Score: 0.116
  16. Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. Am J Transplant. 2016 Jan; 16(1):121-36.
    View in: PubMed
    Score: 0.109
  17. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, Karumanchi SA, Briscoe DM. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013 Jan; 32(1):120-8.
    View in: PubMed
    Score: 0.091
  18. Riella LV, Ueno T, Batal I, De Serres SA, Bassil R, Elyaman W, Yagita H, Medina-Pestana JO, Chandraker A, Najafian N. Blockade of Notch ligand d1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation. J Immunol. 2011 Nov 01; 187(9):4629-38.
    View in: PubMed
    Score: 0.083
  19. Riella LV, Watanabe T, Sage PT, Yang J, Yeung M, Azzi J, Vanguri V, Chandraker A, Sharpe AH, Sayegh MH, Najafian N. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011 Apr; 11(4):832-40.
    View in: PubMed
    Score: 0.080
  20. Bedi DS, Riella LV, Tullius SG, Chandraker A. Animal models of chronic allograft injury: contributions and limitations to understanding the mechanism of long-term graft dysfunction. Transplantation. 2010 Nov 15; 90(9):935-44.
    View in: PubMed
    Score: 0.078
  21. Salama AD, Yuan X, Nayer A, Chandraker A, Inobe M, Uede T, Sayegh MH. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant. 2003 Apr; 3(4):390-5.
    View in: PubMed
    Score: 0.046
  22. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol. 2001 Nov 15; 167(10):5522-6.
    View in: PubMed
    Score: 0.042
  23. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol. 2001 Nov; 12(11):2500-2506.
    View in: PubMed
    Score: 0.042
  24. Kim KS, Denton MD, Chandraker A, Knoflach A, Milord R, Waaga AM, Turka LA, Russell ME, Peach R, Sayegh MH. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol. 2001 Mar; 158(3):977-86.
    View in: PubMed
    Score: 0.040
  25. Onodera K, Chandraker A, Volk HD, Ritter T, Lehmann M, Kato H, Sayegh MH, Kupiec-Weglinski JW. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation. 1999 Jul 27; 68(2):288-93.
    View in: PubMed
    Score: 0.036
  26. Onodera K, Chandraker A, Kato H, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Transplant Proc. 1999 Feb-Mar; 31(1-2):876-7.
    View in: PubMed
    Score: 0.035
  27. Kato H, Onodera K, Chandraker A, Volk HD, Sayegh MH, Kupiec-Weglinski JW. CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients. Transplant Proc. 1998 Jun; 30(4):1063-4.
    View in: PubMed
    Score: 0.033
  28. Schaub M, Stadlbauer TH, Chandraker A, Vella JP, Turka LA, Sayegh MH. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol. 1998 May; 9(5):891-8.
    View in: PubMed
    Score: 0.033
  29. Onodera K, Chandraker A, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW. Agonistic and antagonistic interactions between CTLA4Ig and donor alloantigens in sensitized rat recipients of cardiac allografts. Transplant Proc. 1998 Feb; 30(1):16-8.
    View in: PubMed
    Score: 0.032
  30. Onodera K, Chandraker A, Schaub M, Stadlbauer TH, Korom S, Peach R, Linsley PS, Sayegh MH, Kupiec-Weglinski JW. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J Immunol. 1997 Aug 15; 159(4):1711-7.
    View in: PubMed
    Score: 0.031
  31. Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharp? S, Kupiec-Weglinski JW. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997 May 27; 63(10):1495-500.
    View in: PubMed
    Score: 0.031
  32. Onodera K, Hancock WW, Graser E, Volk HD, Lehmann M, Chandraker A, Sayegh MH, Kupiec-Weglinski JW. Th2-type cytokines in the "infectious" tolerance pathway. Transplant Proc. 1997 Feb-Mar; 29(1-2):1290-1.
    View in: PubMed
    Score: 0.030
  33. Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 01; 187(3):1113-9.
    View in: PubMed
    Score: 0.020
  34. Yuan X, Salama AD, Dong V, Schmitt I, Najafian N, Chandraker A, Akiba H, Yagita H, Sayegh MH. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol. 2003 Mar 15; 170(6):2949-55.
    View in: PubMed
    Score: 0.012
  35. Chowdhury NC, Saborio DV, Garrovillo M, Chandraker A, Magee CC, Waaga AM, Sayegh MH, Jin MX, Oluwole SF. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Transplantation. 1998 Oct 27; 66(8):1059-66.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.